ADALAT LA 30 TABLET 30 mg

Valsts: Singapūra

Valoda: angļu

Klimata pārmaiņas: HSA (Health Sciences Authority)

Nopērc to tagad

Lietošanas instrukcija Lietošanas instrukcija (PIL)
08-11-2012
Produkta apraksts Produkta apraksts (SPC)
07-12-2017

Aktīvā sastāvdaļa:

NIFEDIPINE

Pieejams no:

BAYER (SOUTH EAST ASIA) PTE LTD

ATĶ kods:

C08CA05

Deva:

30 mg

Zāļu forma:

TABLET, FILM COATED

Kompozīcija:

NIFEDIPINE 30 mg

Ievadīšanas:

ORAL

Receptes veids:

Prescription Only

Ražojis:

Bayer AG

Autorizācija statuss:

ACTIVE

Autorizācija datums:

1994-05-05

Lietošanas instrukcija

                                 Adalat LA PI_SG_CCDS16_ 27 Jun 2012 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
      
Instructions for use 
 
 
 
 
Please read carefully! 
 
 
 
 
 
Active ingredient: nifedipine 
Extended release tablets 
 
 
 
 
 
 
 Coronary therapeutic/antihypertensive 
                     active ingredient nifedipine 
 
              Extended release tablets 
 
 
 PRESCRIPTION USE ONLY 
 
 
QUANTITATIVE COMPOSITION 
  
ADALAT LA 20 : 1 prolonged-release tablet contains 20
mg nifedipine  
ADALAT LA 30 : 1 prolonged-release tablet contains 30
mg nifedipine  
ADALAT LA 60 : 1 prolonged-release tablet contains 60
mg nifedipine  
 
PHARMACEUTICAL FORM 
 
Adalat LA 20: Round, convex prolonged-release tablet with
pink coat, laser hole on one side 
and ADALAT20 on the other. 
Adalat LA 30: Round, convex prolonged-release tablet with
pink coat, laser hole on one side 
and ADALAT30 on the other. 
Adalat LA 60: Round, convex prolonged-release tablet with
pink coat, laser hole on one side 
and ADALAT60 on the other. 
 
PHARMACODYNAMIC PROPERTIES 
 
Nifedipine is a calcium antagonist of the 1,4-dihydropyridine
type. Calcium antagonists reduce 
the transmembranal influx of calcium ions through the
slow calcium channel into the cell. 
Nifedipine acts particularly on the cells of the myocardium and
the smooth muscle cells of the 
coronary arteries and the peripheral resistance vessels. 
 
In the heart nifedipine dilates the coronary arteries, especially the
large conductance vessels, 
even in the free wall segment of partially stenosed
areas. Further, nifedipine reduces the 
vascular smooth muscle tone in the coronary arteries and
prevents vasospasm. The end-result 
is an increased poststenotic blood flow and an increased oxygen
supply. Parallel to this, 
nifedipine reduces the oxygen
requirement by lowering p
                                
                                Izlasiet visu dokumentu
                                
                            

Produkta apraksts

                                Adalat LA PI_CCDS17_October 2017
1
INSTRUCTIONS FOR USE
PLEASE READ CAREFULLY!
ADALAT® LA
ACTIVE INGREDIENT: NIFEDIPINE
Coronary therapeutic/antihypertensive
Extended release tablets
PRESCRIPTION USE ONLY
EXTENDED RELEASE TABLETS
ACTIVE INGREDIENT NIFEDIPINE
QUANTITATIVE COMPOSITION
ADALAT LA 20 : 1 prolonged-release tablet contains 20 mg nifedipine
ADALAT LA 30 : 1 prolonged-release tablet contains 30 mg nifedipine
ADALAT LA 60 : 1 prolonged-release tablet contains 60 mg nifedipine
PHARMACEUTICAL FORM
Adalat LA 20: Round, convex prolonged-release tablet with pink coat,
laser hole on one side
and ADALAT20 on the other.
Adalat LA 30: Round, convex prolonged-release tablet with pink coat,
laser hole on one side
and ADALAT30 on the other.
Adalat LA 60: Round, convex prolonged-release tablet with pink coat,
laser hole on one side
and ADALAT60 on the other.
PHARMACODYNAMIC PROPERTIES
Nifedipine is a calcium antagonist of the 1,4-dihydropyridine type.
Calcium antagonists reduce
the transmembranal influx of calcium ions through the slow calcium
channel into the cell.
Nifedipine acts particularly on the cells of the myocardium and the
smooth muscle cells of the
coronary arteries and the peripheral resistance vessels.
In the heart nifedipine dilates the coronary arteries, especially the
large conductance vessels,
even in the free wall segment of partially stenosed areas. Further,
nifedipine reduces the vascular
smooth muscle tone in the coronary arteries and prevents vasospasm.
The end-result is an
increased poststenotic blood flow and an increased oxygen supply.
Parallel to this, nifedipine
reduces the oxygen requirement by lowering peripheral resistance
(afterload). With long-term
use nifedipine can also prevent the development of new atherosclerotic
lesions in the coronary
arteries.
Nifedipine reduces the smooth muscle tone of the arterioles, thus
lowering the increased
peripheral resistance and consequently the blood pressure. At the
beginning of the nifedipine
treatment there may be a transient reflex increase in he
                                
                                Izlasiet visu dokumentu
                                
                            

Meklēt brīdinājumus, kas saistīti ar šo produktu